“Early Toxicology-Markets and Approaches” predicts that pharmaceutical companies and their suppliers will help grow the early toxicology market from $947 million to $1.52 billion by 2010. This market growth will be spurred on by pharmaceutical companies being anxious to develop new technologies which will decrease the costs of drug development and screen out toxic compounds as early as possible.
Toxicity is a crucial parameter in drug development and is measured right through the development process. In fact, toxic side-effects are one of the most common reasons drug candidates fail.
In the past, toxicology was measured only after a drug was developed because the toxicology testing process was both time consuming and expensive and it made logistical sense to carry out procedures only after drug candidates had passed all other criteria to become successful drugs. Soon the aim was to find approaches that would predict toxicology at an earlier stage, and more cheaply.
Current toxicology testing approaches have emerged from this scenario, but differ widely. All approaches, whether in-silico, in-vitro, or in-vivo, detect unfavorable toxicity in drugs earlier.
The report says that toxicity is also the most challenging aspect of a drug to screen as it cannot be contained by a single parameter. It can be a factor of dose, the form in which the drug is administered, or even the time of exposure before elimination. Patient responses also differ widely, depending on age, metabolism and other products in the patient's system.
Analysts believe that there are several approaches to toxicology determinations. Pharma companies will continue to apply fresh approaches and search for new tools to better predict early signs of toxicity, say authors of the report.
The report examines present and emerging technologies and techniques, issues, and opportunities related to early toxicology testing in drug discovery. It pinpoints some of the ways that big pharma companies approach detecting toxicity and includes current and projected market analysis for in-silico, in-vitro, and in-vivo early toxicology products. The study benefits from expert opinion on basic issues within the industry and profiles 30 key suppliers,their products and market approach.
“ Early Toxicology-Markets and Approaches” is available from Report Buyer. For more information go to: http://www.reportbuyer.com/
Report Buyer product ID: KAL00025
